307 related articles for article (PubMed ID: 36769825)
1. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.
Terui H; Asano Y
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769825
[TBL] [Abstract][Full Text] [Related]
2. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome.
Trovato E; Rubegni P; Prignano F
Expert Opin Biol Ther; 2022 Dec; 22(12):1443-1448. PubMed ID: 35726639
[TBL] [Abstract][Full Text] [Related]
3. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
4. Psoriasis and Vascular Risk : An Update.
Katsiki N; Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
Curr Pharm Des; 2014; 20(39):6114-25. PubMed ID: 24745923
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.
Tsiogka A; Gregoriou S; Stratigos A; Soulaidopoulos S; Rompoti N; Panagakis P; Papoutsaki M; Kostakis P; Kontochristopoulos G; Tsioufis K; Campanati A; Offidani A; Vlachopoulos C; Rigopoulos D
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830855
[TBL] [Abstract][Full Text] [Related]
6. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Späh F
Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910
[TBL] [Abstract][Full Text] [Related]
7. Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies.
Kaiser H; Näslund-Koch C; Kvist-Hansen A; Skov L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):303-321. PubMed ID: 38291285
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis and cardiovascular disease: the elusive link.
Manolis AA; Manolis TA; Melita H; Manolis AS
Int Rev Immunol; 2019; 38(1):33-54. PubMed ID: 30457023
[TBL] [Abstract][Full Text] [Related]
9. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis a Cause of Cardiovascular Diseases: A Review Article.
Gupta A; Madke B
Cureus; 2022 Aug; 14(8):e27767. PubMed ID: 36106203
[TBL] [Abstract][Full Text] [Related]
11. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
Furue K; Ito T; Furue M
Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Involvement in Psoriasis, Diagnosing Subclinical Atherosclerosis, Effects of Biological and Non-Biological Therapy: A Literature Review.
Valaiyaduppu Subas S; Mishra V; Busa V; Antony I; Marudhai S; Patel M; Cancarevic I
Cureus; 2020 Oct; 12(10):e11173. PubMed ID: 33262910
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences.
Boehncke WH; Boehncke S
G Ital Dermatol Venereol; 2008 Oct; 143(5):307-13. PubMed ID: 18833072
[TBL] [Abstract][Full Text] [Related]
14. microRNAs involved in psoriasis and cardiovascular diseases.
Sileno S; Beji S; D'Agostino M; Carassiti A; Melillo G; Magenta A
Vasc Biol; 2021; 3(1):R49-R68. PubMed ID: 34291190
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis.
Wang Y; Zang J; Liu C; Yan Z; Shi D
Front Immunol; 2022; 13():835671. PubMed ID: 35514987
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study.
Ahmed N; Prior JA; Chen Y; Hayward R; Mallen CD; Hider SL
Clin Rheumatol; 2016 Dec; 35(12):3069-3073. PubMed ID: 27485152
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study.
Fernández-Armenteros JM; Gómez-Arbonés X; Buti-Soler M; Betriu-Bars A; Sanmartin-Novell V; Ortega-Bravo M; Martínez-Alonso M; Garí E; Portero-Otín M; Santamaria-Babi L; Casanova-Seuma JM
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):128-135. PubMed ID: 29953676
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.
Hu SC; Lan CE
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29065479
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic disorders in patients with psoriasis].
Sikora-Grabka E; Adamczak M; Wiecek A
Przegl Lek; 2011; 68(12):1193-8. PubMed ID: 22519279
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis and cardiovascular disorders.
Frieder J; Ryan C
G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
